apl. Prof. Dr. Stefan Krause

Medizinische Fakultät Department of Medicine 5 – Haematology and Oncology

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations (2022) Eckardt JN, Stoelzel F, Kunadt D, Roellig C, Stasik S, Wagenfuehr L, Joehrens K, et al. Journal article Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD (2022) Stasik S, Kramer M, Zukunft S, Rollig C, Baldus CD, Platzbecker U, Serve H, et al. Journal article Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study (2022) Middeke JM, Metzeler KH, Rollig C, Kramer M, Eckardt JN, Stasik S, Greif PA, et al. Journal article CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome (2022) Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, et al. Journal article Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry (2022) Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schaefer-Eckart K, Steffen B, Sauer T, et al. Journal article Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative (2021) Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021) Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al. Conference contribution Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Conference contribution Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience (2021) Enssle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Conference contribution